Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Cell Therapy"


3 mentions found


AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
  + stars: | 2022-11-29 | by ( ) www.reuters.com   time to read: +2 min
Nov 29 (Reuters) - AstraZeneca (AZN.L) will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday, seeking to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis (NOVN.S) and Gilead (GILD.O). Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells. Linnemann founded Neogene in the Netherlands in 2018 along with the Netherlands Cancer Institute's Ton Schumacher. AstraZeneca will make an initial payment of $200 million to Neogene, with a further $120 million dependent on the company meeting certain targets.
Morgan Stanley said Japanese biotech firm SanBio 's stock could rise by 398% in the next year. The bank has a price target of 4,100 yen ($28) on the stock, which closed at 824 yen Thursday. Morgan Stanley's bullish take on the stock, outlined in a note on global equities to clients on Oct. 28 , comes despite a delay in the approval of the company's traumatic brain injury treatment. However, equity analysts covering the pharmaceutical sector at Nomura, Japan's largest investment bank, remain confident that the treatment will be approved. Morgan Stanley's analysts also said the company will raise sufficient capital in its latest funding round and won't require further cash injection from shareholders.
A decade ago, CAR T cell therapy changed the world of cancer treatment, offering a personalized approach to patients with blood cancers like leukemia. A novel approach to CAR T (chimeric antigen receptor T cell) therapy aims to cut down that turnaround time significantly. Instead of reprogramming each patient's cells, researchers are testing the safety of using universal, or "off the shelf," CAR T cells from other patients, preprogrammed to fight cancer. Scientists at University College London in the United Kingdom tested the safety of the experimental approach in six children — mostly toddlers — with advanced leukemia. One particular side effect associated with CAR T therapy is called a cytokine storm, and it can be deadly.
Total: 3